Lecigon

Entacapone, the active ingredient in Lecigon, is a COMT inhibitor; DOPA decarboxylase inhibitor; dopamine precursor presented as an oral tablet for intestinal use. It is used to manage Parkinson's disease by enhancing and prolonging the effect of levodopa in patients who require stable motor control.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigon is prescribed as part of combination therapy for Parkinson's disease, targeting dopaminergic pathways to improve motor function. - Parkinson's disease (motor fluctuations): reduces OFF periods and improves overall motor performance. - Parkinson's disease (early-stage): augments levodopa response when initiating therapy. - Parkinson's disease (advanced-stage): helps maintain consistent dopamine levels to lessen dyskinesia risk.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring shortly after dosing. - Dyskinesia: involuntary movements due to excess dopamine. - Orthostatic hypotension: dizziness upon standing. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated transaminases. - Neuroleptic malignant syndrome: high fever, muscle rigidity. - Anaphylactic reaction: swelling, airway compromise. - Hyperpyrexia: dangerously high body temperature. - Hematologic abnormalities: neutropenia, thrombocytopenia. - Cardiac arrhythmias: irregular heart rhythm.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Renal function assessment: adjust therapy in severe impairment. - Cardiovascular caution: avoid in uncontrolled hypertension or arrhythmias. - Dyskinesia vigilance: educate patients about early signs. - Abrupt discontinuation avoidance: taper under medical supervision. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lecigon may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - MAO‑B inhibitors (e.g., selegiline): potentiates dopaminergic effects. - Anticholinergic agents: may exacerbate confusion.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible additive blood pressure lowering. - Iron supplements: may reduce levodopa absorption. - Antacids containing aluminum or magnesium: interfere with drug bioavailability.